D. E. Shaw & Co. Inc. Cuts Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

D. E. Shaw & Co. Inc. trimmed its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 15.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,723,706 shares of the biotechnology company's stock after selling 660,971 shares during the period. D. E. Shaw & Co. Inc. owned approximately 2.45% of Heron Therapeutics worth $5,697,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in HRTX. Nicolet Advisory Services LLC acquired a new stake in Heron Therapeutics in the fourth quarter valued at approximately $25,000. Argent Advisors Inc. bought a new position in shares of Heron Therapeutics in the 4th quarter worth $31,000. Cutter & CO Brokerage Inc. lifted its holdings in shares of Heron Therapeutics by 69.6% in the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 13,600 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Heron Therapeutics by 23.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 8,684 shares during the period. Finally, Arkadios Wealth Advisors bought a new stake in Heron Therapeutics during the 4th quarter valued at $76,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th. Wall Street Zen lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday.

Heron Therapeutics Price Performance

Shares of NASDAQ HRTX traded up $0.01 during trading on Thursday, hitting $1.89. The stock had a trading volume of 55,365 shares, compared to its average volume of 2,284,852. The firm has a fifty day moving average of $2.11 and a two-hundred day moving average of $1.82. The company has a market capitalization of $287.58 million, a PE ratio of -10.47 and a beta of 1.33. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to analysts' expectations of $37.08 million. On average, equities analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.